New hope is emerging for patients with treatment-resistant metastatic skin cancer.
At the congress of the European Society of Medical Oncology (Esmo), in Paris, a Dutch team aroused great interest by presenting its research on cell therapies.
This treatment track, launched in the 1980s, had passed into the shadows in the 2010s in the face of the spectacular results of immunotherapy.
To discover
OUR FILE - Elizabeth II, a rock and a symbol for England
But everything comes at the right time to who knows how to wait.
Cell therapy, also called TIL for "tumor
-
infiltratinglymphocytes", is back in the light thanks to this work showing its superiority over ipilimumab (the first immunotherapy authorized on the market in 2011) for certain patients in whom first-line treatments do not work.
In a phase 3 randomized trial including 168 patients, 20% of those treated with cell therapy had a complete response after more than three years of follow-up, compared to 7%…
This article is for subscribers only.
You have 82% left to discover.
Pushing back the limits of science is also freedom.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
